Polyclonal and monoclonal antibodies in renal transplant: An update

Amna Ilahe, Pooja Budhiraja, B. Kaplan

    Research output: Contribution to journalReview articlepeer-review

    2 Scopus citations


    Purpose of review There are several monoclonal and polyclonal antibodies used in renal transplantation today, this article will discuss several agents, their updates and newer agents. Recent findings Antithymocyte globulin and interleukin-2 (IL-2) receptor blocker continue to be used as induction agents. The risk of acute rejection was higher in IL-2 receptor blockers mainly in the first year, but graft survivals were similar in both groups long term. Belatacept is the only approved intravenous maintenance immunosuppressive therapy which provides the benefit of glomerular filtration rate preservation, but it was associated with a higher risk of acute rejection and post-transplant lymphoproliferative disorder. Bortezomib may help decrease donor-specific antibody levels, but there are limited data to support its use for desensitization or rejection. Eculizumab may help in antibody-mediated rejection in some cases but has not shown promising long-term effects in high-risk individuals. Newer agents have been continuously tested for improved efficacy and safety. Summary Transplantation is the standard of care for end-stage renal disease patients, but we still have a long way to go, as we need to improve long-term outcomes. The manipulation of the immune system is a delicate undertaking, with risks of adverse events; therefore, risk versus benefit needs to be carefully evaluated and treatment needs to be individualized.

    Original languageEnglish (US)
    Pages (from-to)563-569
    Number of pages7
    JournalCurrent Opinion in Nephrology and Hypertension
    Issue number6
    StatePublished - Oct 9 2015


    • Antibodies
    • Biologics
    • Monoclonal
    • Newer agents
    • Polyclonal
    • Renal transplant

    ASJC Scopus subject areas

    • Internal Medicine
    • Nephrology


    Dive into the research topics of 'Polyclonal and monoclonal antibodies in renal transplant: An update'. Together they form a unique fingerprint.

    Cite this